medigraphic.com
Colegio de Medicina Interna de México.

2005, Number 6

<< Back Next >>

Med Int Mex 2005; 21 (6)

Creutzfeldt-Jakob disease. A report of three cases and literature review

Pérez CE, Fernández VJA, Herrera CM

Language: Spanish
References: 14
Page: 473-476
PDF size: 65.46 Kb.


ABSTRACT

Creutzfeldt-Jakob encephalitis is a serious infectious-inflammatory disorder of progressive nature, with an annual mortality rate of almost 90%. Since neuroimage studies are of unspecific diagnostic value, the appropriate work-up includes the application of the electroencephalographic assessment (with the typical evidence of periodic patterns), the neuropathological and the immunochemical examinations. In Mexico there are just few reports of this entity, with the highest prevalence in the northern regions; nonetheless we must take into account that most cases are either not reported nor appropriately diagnosed, which leads to an underestimation of the real prevalence of the disease. This must be considered in the presence of a rapidly progressive dementia syndrome in less than 2 months, and in the absence of a demonstrable underlying organic substrate. Three reports of this form of encephalitis, as well as a brief analysis of the most recent information on this condition are presented.


REFERENCES

  1. Glatzel M, Rogivue C, Ghani A, et al. Incidence of Creutzfeldt-Jakob disease in Switzerland. Lancet 2002;360:139-41.

  2. Lorains JW, Agbamu DA, Rossi M, et al. Variant Creutzfeldt-Jakob disease in an elderly patient. Lancet 2001;357:1339-40.

  3. Taratuto AL, Piccardo P, Reich EC, et al. Insomnia associated with thalamic involvement in E200K Creutzfeldt-Jakob disease. Neurology 2002;58:362-7.

  4. Vrancken AF, Frijns CJ, Ramos LM. FLAIR MRI in sporadic Creutzfeld-Jakob disease. Neurology 2000;55:147-8.

  5. Chapman T, Mckeel DW, Morris JC. Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000;55:1396-7.

  6. Silverdale M, Leach JP, Chadwick DW. New variant Creutzfeldt-Jakob disease presenting as localization-related epilepsy. Neurology 2000;54:2188.

  7. Otto M, Wiltfang J, Cepek L, et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2002;58:192-7.

  8. Aksamit AJ, Preissner CM, Homburger HA. Quantitation of 14-3-3 and neuron-specific enolase proteins in CSF in Creutzfeldt-Jakob disease. Neurology 2001;57:728-30.

  9. Gibbons R, Holman RC, Belay ED. Creutzfeldt-Jakob disease in the United States 1979-1998. JAMA 2000;284:2322-3.

  10. Andrews NJ, Farrington CP, Cousens SN, et al. Incidence of variant Creutzfeldt-Jakob disease in the UK. Lancet 2000;356:481-2.

  11. Houston F, Foster JD, Chong A, Hunter N. Transmission of BSE by blood transfusion in sheep. Lancet 2000;356:999-1000.

  12. Ricketts, Maura N. Is Creutzfeldt-Jakob disease transmitted in blood? Is the absence of evidence of risk evidence of the absence of risk?. Can Med Assoc J 1997;157:1367-70.

  13. Hoshi K, Yoshino H, Urata J, et al. Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts in Japan. Neurology 2000;55:718-21.

  14. Stanley Prusiner. Old drugs to treat new variant Creutzfeldt-Jakob disease. Lancet 2001;358:563.




2020     |     www.medigraphic.com